Must-Know Facts About Cannabidiol (CBD)
CBD, or cannabidiol, is quickly changing the debate surrounding the use of marijuana as a medicine.
Most people have heard of a chemical called THC, which is the ingredient in marijuana that gets users high. But recently, attention has shifted to another compound in marijuana called CBD — and for good reason.
Because while doctors can’t seem to look past certain side effects of THC, CBD doesn’t appear to present that problem. On the other hand, evidence of CBD’s medical benefits continues to grow.
Here are five facts that you should know about this unique compound:
CBD is one of over 60 compounds found in cannabis that belong to a class of molecules called cannabinoids. Of these compounds, CBD and THC are usually present in the highest concentrations, and are therefore the most recognized and studied.
CBD and THC levels tend to vary among different plants. Marijuana grown for recreational purposes often contains more THC than CBD.
However, by using selective breeding techniques, cannabis breeders have managed to create varieties with high levels of CBD and next to zero levels of THC. These strains are rare but have become more popular in recent years.
Unlike THC, CBD does not cause a high. While this makes CBD a poor choice for recreational users, it gives the chemical a significant advantage as a medicine, since health professionals prefer treatments with minimal side effects.
CBD is non-psychoactive because it does not act on the same pathways as THC. These pathways, called CB1 receptors, are highly concentrated in the brain and are responsible for the mind-altering effects of THC.
A 2011 review published in Current Drug Safety concludes that CBD “does not interfere with several psychomotor and psychological functions.” The authors add that several studies suggest that CBD is “well tolerated and safe” even at high doses.
Although CBD and THC act on different pathways of the body, they seem to have many of the same medical benefits. According to a 2013 review published in the British Journal of Clinical Pharmacology, studies have found CBD to possess the following medical properties:
|Medical Properties of CBD||Effects|
|Antiemetic||Reduces nausea and vomiting|
|Anticonvulsant||Suppresses seizure activity|
|Antipsychotic||Combats psychosis disorders|
|Anti-inflammatory||Combats inflammatory disorders|
|Anti-oxidant||Combats neurodegenerative disorders|
|Anti-tumoral/Anti-cancer||Combats tumor and cancer cells|
|Anxiolytic/Anti-depressant||Combats anxiety and depression disorders|
Unfortunately, most of this evidence comes from animals, since very few studies on CBD have been carried out in human patients.
But a pharmaceutical version of CBD was recently developed by a drug company based in the UK. The company, GW Pharmaceuticals, is now funding clinical trials on CBD as a treatment for schizophrenia and certain types of epilepsy.
Likewise, a team of researchers at the California Pacific Medical Center, led by Dr. Sean McAllister, has stated that they hope to begin trials on CBD as a breast cancer therapy.
CBD seems to offer natural protection against the marijuana high. Numerous studiessuggest that CBD acts to reduce the intoxicating effects of THC, such as memory impairment and paranoia.
CBD also appears to counteract the sleep-inducing effects of THC, which may explain why some strains of cannabis are known to increase alertness.
Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.
Porter BE, Jacobson C. Epilepsy Behav. 2013 Dec;29(3):574-7.
Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression.
Amada N, Yamasaki Y, Williams CM, Whalley BJ. PeerJ. 2013 Nov 21;1:e214.
Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, Burnett MD, Yamasaki Y, Stephens GJ, Whalley BJ, Williams CM.Seizure. 2012 Jun;21(5):344-52
Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Pharmacol Ther. 2012 Jan;133(1):79-97
Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules.
Scott KA, Shah S, Dalgleish AG, Liu WM. Anticancer Res. 2013 Oct;33(10):4373-80.
Massi P, Solinas M, Cinquina V, Parolaro D. Br J Clin Pharmacol. 2013 Feb;75(2):303-12
Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C. Cancer Treat Rev. 2012 Nov;38(7):911-8
Izzo AA, Camilleri M. Pharmacol Res. 2009 Aug;60(2):117-25.
Di Marzo V, Piscitelli F, Mechoulam R. Handb Exp Pharmacol. 2011;(203):75-104.
Kim W, Doyle ME, Liu Z, Lao Q, Shin YK, Carlson OD, Kim HS, Thomas S, Napora JK, Lee EK, Moaddel R, Wang Y, Maudsley S, Martin B, Kulkarni RN, Egan JM. Diabetes. 2011 Apr;60(4):1198-209.
Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle.
Silvestri C, Ligresti A, Di Marzo V. Rev Endocr Metab Disord. 2011 Sep;12(3):153-62.
Effect of dietary fat on endocannabinoids and related mediators: consequences on energy homeostasis, inflammation and mood.
Banni S, Di Marzo V. Mol Nutr Food Res. 2010 Jan;54(1):82-92.
Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H. Eur J Gastroenterol Hepatol. 2011 Oct;23(10):891-6.
Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Isr Med Assoc J. 2011 Aug;13(8):455-8.
Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study.
Lahat A, Lang A, Ben-Horin S. Digestion. 2012;85(1):1-8.
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis.
Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, Guadagno F, Petrosino S, Capasso F, Di Marzo V, Izzo AA. J Mol Med (Berl). 2009 Nov;87(11):1111-21.
Robson PJ, Guy GW, Di Marzo V. Curr Pharm Des. 2013 Jun 14. [Epub ahead of print]
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Transl Psychiatry. 2012 Mar 20;2:e94